OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
20
Results
Show all
Save search
Copy query
Show results for
Unknown
(20)
Publication Date
Release Date
2020
(4)
2025
(3)
2023
(3)
2022
(3)
2024
(2)
2021
(2)
2019
(1)
2017
(1)
2016
(1)
Previous
page
1 / 2
You're on page
1
page
2
Next
page
Sort
by:
Relevance
Page size
10
Novel mutations in
dystonin
provide clues to the pathomechanisms of HSAN-VI.
Not available
S-EPMC5447400
|
biostudies-literature
Cite
Contribution of Skin Biopsy in Peripheral Neuropathies.
Not available
S-EPMC7765344
|
biostudies-literature
Cite
Nerve conduction velocity in CMT1A: what else can we tell?
Not available
S-EPMC5603914
|
biostudies-literature
Cite
Value of Antibody Determinations in Chronic Dysimmune Neuropathies.
Not available
S-EPMC9856104
|
biostudies-literature
Cite
Brain Plasticity in Charcot-Marie-Tooth Type 1A Patients? A Combined Structural and Diffusion MRI Study.
Not available
S-EPMC7506188
|
biostudies-literature
Cite
A Novel
CAPN1
Mutation Causes a Pure Hereditary Spastic Paraplegia in an Italian Family.
Not available
S-EPMC6560055
|
biostudies-literature
Cite
Clinical criteria and diagnostic assessment of fibromyalgia: position statement of the Italian Society of Neurology-Neuropathic Pain Study Group.
Not available
S-EPMC10257633
|
biostudies-literature
Cite
Real-life experience with inotersen in hereditary transthyretin amyloidosis with late-onset phenotype: Data from an early-access program in Italy.
Not available
S-EPMC9314115
|
biostudies-literature
Cite
Long-term treatment of hereditary transthyretin amyloidosis with patisiran: multicentre, real-world experience in Italy.
Not available
S-EPMC11306272
|
biostudies-literature
Cite
Frequency, entity and determinants of fatigue in Charcot-Marie-Tooth disease.
Not available
S-EPMC10107642
|
biostudies-literature
Cite
Previous
page
1 / 2
You're on page
1
page
2
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets